Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: A retrospective study

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 361-364

  Saifan, Chadi ^a   El Charabaty, Elie ^a   El Sayegh, Suzanne ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Hemodialysis; Hyperhomocysteinemia; Vascular access thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; THROMBOSIS; VASCULAR ACCESS THROMBOSIS;

HEMODIALYSIS; HYPERHOMOCYSTEINEMIA; VASCULAR ACCESS THROMBOSIS;

AGED; ASPIRIN; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DIABETES COMPLICATIONS; FEMALE; FIBRINOLYTIC AGENTS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; UP-REGULATION;

EID: 84880606956     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S47255     Document Type: Article

References (21)

1. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA. Hemodialysis vascular access morbidity in the United States. Kidney Int. 1993;43(5):1091-1096.
2. Choudhury D. Vascular access thrombosis prophylaxis. Semin Dial. 2006;19(4):335-342.
3. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int. 1999;55(1):315-320.
4. Heard KA, Russell TA. Access thrombosis, hospitalization, and hematocrit level in hemodialysis patients. Nephrol Nurs J. 2000;27(6): 607-611.
5. Fukasawa M, Matsushita K, Kamiyama M, et al. The methylenetet-rahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003;41(3):637-642.
6. Lentz SR. Homocysteine and cardiovascular physiology. In: Carmel R, Jacobsen DW, editors. Homocysteine in Health and Disease. New York, NY: Cambridge University Press; 2001.
7. Shemin D, Lapane KL, Bausserman L, et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol. 1999;10(5):1095-1099.
8. Mallamaci F, Bonanno G, Seminara G, et al. Hyperhomocysteinemia and arteriovenous fstula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005;45(4):702-707.
9. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61(2):609-614.
10. Suliman ME, Bárány P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conficting story. Nephrol Dial Transplant. 2005;20(1):16-21.
11. Den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345(8954): 882-885.
12. Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123(10):747-753.
13. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefts of increasing folic acid intakes. JAMA. 1995;274(13): 1049-1057.
14. Bednarek-Skublewska A, Przywara S, Wronski J, Ksiazek A. Influence of homocysteine on the function of native arteriovenous fstula in hemodialysis patients. Dial Transplant. 2006;35(10).
15. Bowden RG, Wyatt FB, Wilson R. Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study. J Nephrol. 2002;15(6):666-670.
16. Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M. Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail. 2004;26(6):709-714.
17. Chen TC, Wang IK, Lee CH, et al. Hyperhomocysteinemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study. Int J Clin Pract. 2006;60(12):1596-1599.
18. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail. 2002;24(2):215-222.
19. Sirrs S, Duncan L, Djurdjev O, et al. Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant. 1999;14(3): 738-743.
20. Goldwasser P, Michel MA, Collier J, et al. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis. 1993;22(1):215-225.
21. Degoulet P, Legrain M, Réach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31(2):103-110.